Share on StockTwits

Regado Biosciences (NASDAQ:RGDO) was downgraded by Cowen and Company from an “outperform” rating to a “market perform” rating in a research note issued on Wednesday, TheFlyOnTheWall.com reports.

Several other analysts have also recently commented on the stock. Analysts at Needham & Company LLC downgraded shares of Regado Biosciences from a “buy” rating to a “hold” rating in a research note on Monday, July 7th. They now have a $13.00 price target on the stock. Separately, analysts at BMO Capital Markets downgraded shares of Regado Biosciences from an “outperform” rating to an “underperform” rating in a research note on Thursday, July 3rd. They now have a $1.00 price target on the stock. Finally, analysts at Wedbush downgraded shares of Regado Biosciences from an “outperform” rating to an “underperform” rating in a research note on Thursday, July 3rd. They now have a $2.00 price target on the stock, down previously from $10.00. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. Regado Biosciences currently has a consensus rating of “Hold” and a consensus price target of $9.67.

Shares of Regado Biosciences (NASDAQ:RGDO) opened at 2.80 on Wednesday. Regado Biosciences has a 52 week low of $2.22 and a 52 week high of $14.10. The stock has a 50-day moving average of $3.57 and a 200-day moving average of $6.50. The company’s market cap is $94.1 million.

Regado Biosciences (NASDAQ:RGDO) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.63) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.51) by $0.12. On average, analysts predict that Regado Biosciences will post $-2.10 earnings per share for the current fiscal year.

Regado Biosciences, Inc is a biopharmaceutical company focused on the discovery and development of actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications.

The Fly On The Wall

Receive News & Ratings for Regado Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regado Biosciences Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.